

Award Number: W81XWH-06-1-0154

TITLE: Genetic and molecular analysis of the mechanisms by which TSC regulates neuronal differentiation

PRINCIPAL INVESTIGATOR: Helen McNeill, Ph.D.

CONTRACTING ORGANIZATION: Mount Sinai Hospital
Toronto, Canada, M5G 1X5

REPORT DATE: February 2008

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE 13-02-2008		2. REPORT TYPE Annual		3. DATES COVERED 14 JAN 2007 - 13 JAN 2008	
4. TITLE AND SUBTITLE Genetic and molecular analysis of the mechanisms by which TSC regulates neuronal differentiation				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0154	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Helen McNeill, Ph.D. Email:				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mount Sinai Hospital Toronto, Canada, M5G 1X5				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT We have shown that TSC plays a key role in controlling the timing of neuronal differentiation in Drosophila through the conserved insulin receptor (InR)/Tor kinase signaling pathway (Bateman & McNeill, 2004). The goal of our current research is to determine the mechanism by which TSC regulates the timing of neuronal differentiation. To uncover the pathway(s) downstream of TSC in the temporal control of neuronal differentiation we are taking complementary approaches. 1) Analysis of minimal regions of neuronal promoters responsive to TSC. 2) Identification and analysis of genes regulated by TSC to control neural differentiation. We find that InR/TSC signaling regulates the transcription and phosphorylation state of the ETS transcription factor, Pointed P2. We define a 2.5kb region of the ELAV neuronal enhancer region that responds to TSC. We have further used transgenic RNAi analysis in vivo to test if candidate genes that are regulated by TSC in a screen of S2 cells have a role in the regulation of neuronal differentiation in vivo, and have identified candidate genes that regulate neuronal differentiation timing in vivo.					
15. SUBJECT TERMS TSC, Insulin Signaling, neuronal differentiation, model organisms, Drosophila					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	61	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	Page
Introduction.....	4
Body.....	.4
Key Research Accomplishments.....	14
Reportable Outcomes.....	.14
Conclusions.....	14
References.....	15
Appendices.....	16


INTRODUCTION: Tuberous Sclerosis complex (TSC) is one of the most common forms of neurocutaneous disorders, affecting 1 in 6000 live births. This autosomal dominant disease typically presents in the pediatric age group with neuropsychiatric signs and symptoms of epilepsy, mental retardation and autism. It is poorly understood how loss of TSC leads to these neurological defects. We have shown that TSC plays a key role in controlling the timing of neuronal differentiation in *Drosophila* through the conserved insulin receptor (InR)/Tor kinase signalling pathway (Bateman & McNeill, 2004). The goal of our current research is to determine the mechanism by which TSC regulates the timing of neuronal differentiation. To uncover the pathway(s) downstream of TSC in the temporal control of neuronal differentiation we are taking three complementary approaches that will address both the transcriptional and translational outputs of the TSC pathway. *Task 1.* Identify minimal region of neuronal promoters responsive to TSC. *Task 2 & Task 3.* Test candidates for control of neural differentiation using an RNAi screen of the *Drosophila* genome.

BODY: Task 1) Analysis of minimal regions of neuronal promoters responsive to TSC. Our preliminary data indicated that loss of TSC leads to increased expression of PntP2 transcript, as assessed by a PntP2 specific enhancer trap, and increased expression of the neural specific splicing factor ELAV (as detailed in the grant application). During year 1 of this proposal, we verified that PntP2 expression increases with RT-PCR (as detailed in the first progress report). To determine the enhancer elements responsible for the increase in PntP2 transcription upon loss of TSC, we made enhancer-reporter constructs, and generated transgenic fly lines carrying the upstream elements of the PntP2 genomic region. Preliminary analysis of these lines indicated that a 4kb element can confer PntP2 expression in the eye imaginal disc. In parallel, we determined that overexpressing PntP2 is not sufficient to drive precocious neuronal differentiation, suggesting other components downstream of TSC are needed for precocious differentiation (McNeill et al, 2008; *Genetics, in press*).

During the past year, we have therefore focused our attention on examining the enhancer region of the Elav promoter for TSC-responsive elements, since ELAV responds to loss of TSC, and loss and gain of function analysis indicates that ELAV is essential for proper neural differentiation. We have also found that loss of TSC leads to phosphorylation of PntP2, providing a potential mechanism to complement the increase of PntP2 in the regulation of neuronal differentiation.


We initiated these studies by cloning fragments of the upstream genomic region of ELAV, to identify potential TSC responsive elements. In our initial studies, we cloned these fragments upstream of a luciferase reporter, transfected these constructs into *S2 Drosophila* cells, and tested if these fragments conferred responsiveness to activation of the Insulin Receptor/TSC pathway by addition of insulin. Two days after transfection, cells were treated with stimulating concentration of insulin for 1h and 24h. These studies revealed that insulin treatment induces a transient increase of luciferase activity for Elav promoter fragment #1 and #2 (upper panel). As a readout to verify the activation of the InR pathway in response to insulin treatment, we also assessed AKT phosphorylation using western blot analysis (lower panel). Lamin B was used as a loading control.

Figure 1. Fragments of the *Elav* promoter respond to insulin treatment in S2 cells




To determine if the response of these fragments to Insulin treatment is physiologically relevant, and if they respond to loss of TSC *in vivo*, we examined the responsiveness of these enhancer elements in transgenic *Drosophila* analysis. We generated transgenic flies with different two reporter constructs where expression of Beta-galactosidase was placed under the control of the 3.5Kbp and the 390bp *Elav* promoter. Loss of function clones of TSC1 were generated in each background, and expression of the reporter was assessed by staining with antibodies to beta-galactosidase. We determined that *TSC1* LOF clones induce an increase in reporter activity when under the control of the 3.5Kb *Elav* promoter fragment, but that *TSC1* LOF clones do not change activity of the reporter when under the control of the 390bp *Elav* promoter fragment (Figure 2). These data indicate that a portion of the *Elav* promoter from -3.0kb to -.4 kb confer responsiveness to TSC *in vivo*.

Figure 2 . *TSC controls expression of ELAV transcription via an element from -3kb to -.4 kb upstream of the ELAV transcript.*



GFP/X-Gal driven by the 3.5kb element /Elav



GFP/X-Gal driven by 390 bp element/Elav


X-Gal expression is increased in *TSC1* LOF clones (marked by the absence of GFP), suggesting that it includes an element responsive to InR/TSC signalling (upper panel). However *TSC1* LOF clones do not alter the expression of X-Gal when driven by the 390bp *Elav* promoter fragment (lower panel).

Regulation of pointed P2 phosphorylation by the InR/TSC pathway

We have previously shown that the InR/TSC pathway specifically regulates the expression levels of the ETS transcription factor pointed P2 (Bateman and McNeill, 2004), and that reduction of pointed P2 expression phenocopies InR/TSC mutants in the regulation of differentiation but not growth (McNeill et al, 2008). Pointed P2 function is dependent on site specific phosphorylation, thus a plausible model is that InR/TSC both increases PntP2 transcription (McNeill et al, 2008) and modulates pointed P2 activity by altering its phosphorylation status. Our preliminary data (below) support this hypothesis


To test if PntP2 is phosphorylated by insulin signaling we conducted *in vivo* labeling experiments with ^{32}P , using S2 cells. After a prelabeling period, we stimulated cells with insulin, lysed cells and immunoprecipitated (IP) with antibodies we generated that were specific to PntP2. SDS-PAGE analysis of the immunoprecipitate, followed by autoradiograph analysis, showed an increase of endogenous phosphorylated-pointed P2 after 30 minutes of treatment with insulin.

Figure 3. Insulin treatment increases pointed P2 phosphorylation in S2 cells.



To determine if PntP2 phosphorylation is specifically increased by removal of TSC, we used a similar labeling protocol, and exposed S2 cells to dsRNA to remove TSC1. We noted that exposure of cells to dsRNA to TSC1 also led to an increase in the phosphorylation of PntP2. Since it is known that phosphorylation of PntP2 is needed for its transcriptional activity, this supports a model in which TSC regulates neuronal differentiation by increasing the phosphorylation of PntP2.

Figure 4. Activation of InR/TOR pathway using TSC1 dsRNA increases pointed P2 phosphorylation



DsRNA against TSC1 efficiently activates InR/TOR signalling as illustrated by the increase of phospho-S6K after 6, 7, and 8 days in culture. (top panel). DsRNA against TSC1 induces an increase of pointed P2 phosphorylation (bottom panel).

Although the signal from the *in vivo* labelling is weak, it seems that both bands corresponding to phospho-pointed P2 are decreased in the presence of dsRNA against pointed P2 in the control experiment and in response to a 30 minutes treatment with insulin. We will optimize this by conducting a detailed time course, and using a more robust protocol in which signal for phospho-pointed P2 is enhanced.

In summary, our preliminary data show that activation of the InR/TSC signaling, either by treating with insulin, or in response to dsRNA against TSC1 increases pointed P2 phosphorylation. We will now determine if the phosphorylation site on PntP2 that is targeted by TSC is the same site that has been previously been described to be the target of MAPK signaling. We already have in the laboratory PntP2 which is mutated at this site, and will use it to determine if the increase in phosphorylation seen upon insulin stimulation is blocked by this mutation.

Task 2 and Task 3. Analysis of candidates for TSC -mediated control of neuronal differentiation using genome-wide RNAi screens and genetic epistasis analysis.


We have previously shown that loss of TSC in the *Drosophila* eye leads to precocious neural differentiation, without altering the specific cell fate decisions (Bateman and McNeill, 2004).

Regulation of growth by the InR/Tor signaling pathway is mediated in part through translational control. In the first year of this grant, as detailed in the previous report, we tested candidates for translational control via an in silico screen of 5'TOP containing genes in a genome-wide analysis. No neuronal proteins that are translated from transcripts with 5'TOPs (including Mnf, ed, dim7, Src42A and Src64B) showed any changes in levels of translation in the absence of tsc or pten, negative regulators of the InR/Tor pathway. Loss of Heph, a 5'TOP binding protein, did not alter the timing of differentiation. Our results suggested that 5'TOP-containing neuronal transcripts are not the link between the InR/Tor growth pathway and the Egfr differentiation pathway. Therefore we continued our analysis of potential control by examining other mechanisms. During the course of the first year of this grant, a study was reported that combined the use of rapamycin, transcriptional profiling, and RNA interference in *Drosophila* tissue culture cells, and identified a set of Tor-regulated genes that control growth (Guertin et al., 2006). As TOR lies downstream of TSC, these genes provide a set of validated targets that have the potential to regulate the timing of neuronal differentiation under the control of the InR/TSC pathway.

We have initiated an in vivo RNAi screen to determine if these genes are involved in controlling the timing of photoreceptor differentiation in vivo. These studies have taken advantage of a new resource, a genome-wide RNAi transgenic *Drosophila* collection (Dietzl et al, 2007), maintained by the VDRC (<http://www.vdrc.at/rnai-library>). The library comprises 22,247 transgenic *Drosophila* strains, each containing an inducible UAS-RNAi construct against a single protein coding gene. 12,251 genes, or 88.2% of the *Drosophila* genome, are represented in this collection. All insertions have been molecularly validated, and a sample also functionally validated. By crossing lines carrying a specific dsRNA to Gal4 driver lines we can determine if genes regulated by the InR/TSC pathway control the timing of differentiation. We have obtained inducible RNAi lines to the candidates, and are in the process of testing. Currently we have examined 11 lines, of which 10 show no effect on the timing of differentiation (for example, see Figure 5). However one line, CG1242, does show altered timing of differentiation (Figure 6). We will continue to screen for genes that regulate the timing of differentiation. For any positives obtained, we will validate


that they function downstream of TSC by genetic epistasis analysis, using both gain-of-function and loss-of-function analysis.

Figure 5. Clones of cells expressing dsRNA for CG6677 (Ash2) do not change the timing of photoreceptor differentiation



RNAi clones for CG6677 (marked by GFP) do not show any alteration in the timing of differentiation of photoreceptor stained by Bar

Figure 6. RNAi clones for CG1242 delay the timing of photoreceptor differentiation




RNAi clones for CG1242 (marked by GFP) show delay in the expression of Bar in PRs, while Elav does not seem to be altered. We could not make clones at a later stage during eye development possibly because of an effect of sustained downregulation of CG1242 on cell viability.

To better understand the signal transduction system downstream of TSC in neuronal differentiation, we have also continued our genetic epistasis analysis of known components of the pathway in the eye imaginal disc. We have found that loss of eIF4E does not affect the timing of differentiation, suggesting it is not a key element of the differentiation control. Strikingly, while loss of S6 has little effect on its own, double mutant clones of S6 and TSC leads to an abrogation

of precocious differentiation, suggesting that S6 activation is crucial to the promotion of differentiation. Finally, we have also tested elements of the nuclear receptor ecdysone pathway, which is also known to regulate the timing of differentiation in the eye, to determine the genetic relationship between these two pathways.

Ecdysone signalling acts as a developmental timer to coordinate tissue differentiation. It controls the progression of the morphogenetic furrow during eye development (Brennan et al, 1998: Figure 7) suggesting that, similarly to InR/TSC signalling, ecdysone regulates the timing of photoreceptor differentiation. Determining the relationship between both pathways may provide us with a mechanism to explain how InR/TSC regulates neuronal differentiation.

Figure 7. The ecdysone receptor (EcR) regulates the timing of photoreceptor differentiation




RNAi clones for EcR (marked by GFP) show efficient downregulation of EcR, and acceleration of photoreceptor differentiation as illustrated by Elav staining.

To determine if the EcR also regulates the timing of neuronal differentiation in other tissues besides the eye primordium, we have examined the effect of loss of function clones of TSC1 and RNAi to EcR in the leg disc and the antennal disc (Figure 9). These studies revealed that EcR and InR/TSC similarly regulate the timing of expression of the neuronal marker Elav in antennal discs.

To determine the epistatic relationship between the InR/TSC pathway and the EcR pathway, we generated clones doubly mutant for both pathways. We used mitotic recombination to generate clones of cells that are mutant for the *InR*, and which simultaneously express dsRNAi for EcR. These clones do not show expression of Elav even when the clone crosses a cluster of Elav-

expressing cells. This suggests that, as for photoreceptors, EcR acts either upstream or in parallel to InR to control the timing of neuronal differentiation in the antennal disc.

Figure 8. Temporal control of neuronal differentiation is similarly regulated by EcR and InR-TSC pathway




RNAi clones for EcR (marked by GFP) show acceleration of differentiation of Bar-expressing photoreceptors (PR1 & 6) and Prospero-expressing photoreceptor R7

To complement this analysis, we also conducted epistasis experiments using mitotic recombination clones which EcR-RNAi/*InR* and examined the expression of the previously characterized EcR target, BrCZ1. We found that these clones show clear upregulation of BrCZ1 in the eye disc. This suggests that InR/TSC pathway acts either upstream or in parallel to EcR to control the expression of BrCZ1.


In addition, we generated loss- of-function clones for InR alone, or in combination with EcR RNAi (Figure 10). We found that there were equivalent delays in each case, consistent with a model in which EcR acts either upstream or in parallel to InR/TSC in the control of the timing of neuronal differentiation.

Figure 9. EcR and TSC regulate neuronal differentiation in the antennal disc.



TSC1^{-/-} and EcR RNAi clones induce precocious expression of Elav in the antennal disc compared to the wild type. Right column displays the percentage of antennal disc stained with Elav. Advancement of the morphogenetic furrow was used to stage discs.

Figure 10. Epistasis experiments show that EcR acts either upstream or in parallel to InR-TSC pathway to control the timing of neuronal differentiation



LOF clones for *InR* alone (top panel) or in combination with RNAi against EcR (lower panel and marked by the presence of GFP) show delay in differentiation of Bar expressing cells. This suggests that EcR acts either upstream or in parallel to InR/TSC signalling in the control of the timing of PR differentiation

Summary: InR/TSC and EcR pathways similarly regulate the timing of neuronal differentiation. Epistasis experiments suggest that EcR acts upstream or in parallel to InR pathway to control this stepwise mechanism. Preliminary data showing that EcR alters AKT activity favors the model in which EcR regulates InR/TSC signalling, although this remains to be confirmed using other markers of the pathway. Future experiments will continue to test the candidates for neuronal differentiation, using the genome-wide RNAi library generated by the VDRC.

KEY RESEARCH ACCOMPLISHMENTS:

- PntP2 enhancer analysis and ELAV enhancer analysis in vitro and in vivo has identified regions responsive to TSC.
- Phosphorylation of PntP2 is induced by loss of TSC or activation of Insulin Receptor signaling, providing a potential dual mechanism for the regulation of the timing of differentiation.
- Genetic epistasis analysis reveals that EcR acts upstream or in parallel to InR pathway to control the timing of neuronal differentiation.
- RNAi screening of candidate genes in vivo has identified one gene (CG1242) that is regulated by TSC that alters the timing of differentiation.

REPORTABLE OUTCOMES. A manuscript is in press, detailing the regulation of PntP2 transcription in TSC mutant clones, and the necessary but not sufficient effects of PntP2 expression (McNeill et al, 2008). A peer-reviewed literature analysis has been written on the intersection of Insulin Receptor signaling and neuronal differentiation (Bateman & McNeill, 2006)

CONCLUSION: Our studies have identified two new downstream targets of the TSC pathway in photoreceptor differentiation in the *Drosophila* eye; PntP2 and Broad Complex. We have tested the hypothesis that 5' TOP containing transcripts and found no evidence to support this model, therefore other modes of translational control will be assessed. We have determined that while PntP2 expression is necessary for neuronal differentiation, and its expression is altered by TSC activity, overexpression of PntP2 is not sufficient to account for the effects of TSC on neuronal differentiation. We have found that PntP2 phosphorylation is enhanced by loss of TSC, suggesting that InR/TSC may regulate the timing of differentiation via control of the transcriptional activity of PntP2. Future studies will focus on identifying additional targets and assessing if they are necessary and sufficient for the neuronal differentiation phenotypes observed upon loss of TSC.

References:

Bateman, J.M. and H. McNeill. (2004). "Temporal control of differentiation by the insulin receptor/Tor pathway in *Drosophila*". *Cell* **119**, 87-96.

Bateman, J.M. & H. McNeill (2006))" Insulin/IGF signalling in neurogenesis" *Cell Mol Life Sci.* 63(15):1701-1705

Brennan CA, Ashburner M, Moses K. "Ecdysone pathway is required for furrow progression in the developing *Drosophila* eye" *Development.* 1998 Jul;125(14):2653-64.

Deitzl et al (2007) "A genome-wide transgenic RNAi library for conditional gene inactivation in *Drosophila*" . *Nature* 448 151-156

Guertin et al, (2006). Functional genomics identifies TOR-regulated genes that control growth and division . *Curr. Biol.* 16(10):958-70.

McNeill, H. Craig, G. and Bateman, JM (2008)) "Regulation of neurogenesis and EGFR signalling by the insulin receptor/TOR pathway in *Drosophila*" *Genetics in press*

**Regulation of neurogenesis and EGFR signalling by the insulin receptor/TOR
pathway in *Drosophila***

Helen McNeill^{*}, Gavin M. Craig[†] and Joseph M. Bateman[†]

^{*}Samuel Lunenfeld Research Institute

Toronto

Ontario M5G 1X5

Canada

[†]The Wolfson Centre For Age-Related Diseases

King's College London

London SE1 1UL

UK

Running title: EGFR and insulin signalling in *Drosophila*

Key words: insulin, TOR, neurogenesis, pointed, MAPK, *Drosophila*

Corresponding Author:

Joseph Bateman

The Wolfson Centre For Age-Related Disease

Hodgking Building

King's College London

Guy's Campus

London SE1 1UL

UK

Tel. (44) 207 848 8144

Fax. (44) 207 848 6814

Email: joseph_matthew.bateman@kcl.ac.uk

Abstract

Determining how growth and differentiation are coordinated is key to understanding normal development, as well as disease states such as cancer, where that control is lost. We have previously shown that growth and neuronal differentiation are coordinated by the insulin receptor/TOR kinase (InR/TOR) pathway. Here we show that the control of growth and differentiation diverge downstream of TOR. TOR regulates growth by controlling the activity of S6 kinase (S6K) and eIF4E. Loss of *s6k* delays differentiation, and is epistatic to the loss of *tsc2*, indicating that S6K acts downstream or in parallel to TOR in differentiation as in growth. However, loss of *eIF4E* inhibits growth but does not affect the timing of differentiation. We also show, for the first time in *Drosophila*, that there is cross-talk between the InR/TOR pathway and epidermal growth factor receptor (EGFR) signalling. InR/TOR signalling regulates the expression of several EGFR pathway components including *pointedP2* (*pntP2*). In addition, reduction of EGFR signalling levels phenocopies inhibition of the InR/TOR pathway in the regulation of differentiation. Together these data suggest that InR/TOR signalling regulates the timing of differentiation through modulation of EGFR target genes in developing photoreceptors.

Introduction

A fundamental challenge during the development of any complex organism is the coordination of proliferation and differentiation. The rate of proliferation is not constant during development (NEUFELD *et al.* 1998) and depends on the developmental stage as well as hormonal and nutritional cues (BRITTON *et al.* 2002). Coordinating growth and differentiation is a particular challenge in complex tissues, such as the nervous system. Neurogenesis is preceded by a period of proliferation, which generates a pool of precursor cells. Selected cells from this pool exit the cell cycle and initiate a complex program of gene expression that will result in the formation of the mature neuron.

The *Drosophila* retina is a highly tractable model for studying the relationship between growth and neuronal differentiation (WOLFF and READY 1993). Photoreceptor (PR) differentiation in *Drosophila* is initiated at the beginning of the third larval instar when a physical indentation, known as the morphogenetic furrow (MF), develops at the posterior of the eye imaginal disc. Over a period of about 48 hours the MF sweeps anteriorly leading to the formation of PR preclusters. The MF is initiated by the morphogen Hedgehog (Hh) and is propagated anteriorly through a combination of Hh and Decapentaplegic (Dpp) signalling (VOAS and REBAY 2004). Posterior to the MF, PRs are specified sequentially through reiterative use of the Notch and EGFR pathways (BRENNAN and MOSES 2000; VOAS and REBAY 2004).

As in other neurogenic contexts, neuronal differentiation in the *Drosophila* eye is a temporally restricted process. Patterning of the mature cluster of eight PRs is highly stereotyped with each row forming about every two hours (Fig. 1A) (WOLFF and READY 1993). The mechanism underlying the temporal control of PR differentiation has proven elusive. Several models have been proposed including control by receptor-mediated cell-cell interactions and intrinsic or extrinsic cellular clocks (BRENNAN and MOSES 2000; FREEMAN 1997; VOAS and REBAY 2004). We found that the conserved InR/TOR pathway plays a key role in controlling the timing of neuronal differentiation in *Drosophila* (BATEMAN and MCNEILL 2004). Using mutants in various components of the InR/TOR pathway, we showed that activation of this pathway causes precocious differentiation of neurons. Conversely, inhibition of InR/TOR signalling significantly delays neurogenesis. How the InR/TOR pathway regulates neuronal differentiation is unclear.

Temporal control of neuronal differentiation is a property of the entire InR/TOR pathway. Ligand binding to the InR causes recruitment and phosphorylation of the insulin receptor substrate (IRS) and subsequent activation of PI3K, which catalyses the production of phosphatidylinositol 3,4,5-trisphosphate (PIP3) at the membrane (LEEVERS and HAFEN 2004). PDK1 and PKB/AKT, both PH domain-containing kinases, become membrane localised by their interaction with PIP3 where PKB/AKT can be fully activated. InR signalling controls growth and proliferation through the inhibition of the GTPase activating protein (GAP) TSC2 (CAI *et al.* 2006; GAO and PAN 2001; POTTER *et al.* 2001; TAPON *et al.* 2001). TSC2 inhibits the activity of the small GTPase Rheb, which activates TOR (LONG *et al.* 2005). TOR is a phosphatidylinositol kinase-related kinase that is part of a complex (TORC1) that

controls growth through the regulation of ribosome biogenesis and translation via S6K and eIF4E respectively (INOKI and GUAN 2006; WULLSCHLEGER *et al.* 2006). TOR is also a component of the TORC2 complex. TORC2 is insensitive to rapamycin and has recently been shown to phosphorylate AKT at Ser473 (GUERTIN *et al.* 2006b; SARBASSOV *et al.* 2005). TOR has other functions including the regulation of microautophagy and fat metabolism (RUSTEN *et al.* 2004; SCOTT *et al.* 2004). In addition, inhibition of TOR by treatment with rapamycin elicits a transcriptional response involving several hundred genes (GUERTIN *et al.* 2006a; PENG *et al.* 2002). Recently a negative feedback loop in which S6K regulates IRS, both transcriptionally and by phosphorylation, has been shown to exist in both *Drosophila* (RADIMERSKI *et al.* 2002) and mammalian systems (HARRINGTON *et al.* 2004; SHAH *et al.* 2004; UM *et al.* 2004).

What is the mechanism by which InR signalling controls the timing of neuronal differentiation? In mammalian systems activation of insulin/IGF receptor tyrosine kinases causes activation of both PI3K and Ras/mitogen activated protein kinase (MAPK) pathways (BALTENSBERGER *et al.* 1993; DOWNWARD 2003; SKOLNIK *et al.* 1993). Ligand binding to the InR results in tyrosine phosphorylation of IRS proteins and/or Shc which, through the adaptor protein Grb2, results in recruitment to the membrane of SOS for the activation of Ras (BALTENSBERGER *et al.* 1993; SKOLNIK *et al.* 1993). However, flies expressing a version of the *Drosophila* IRS *chico*, in which the putative Drk (the *Drosophila* orthologue of Grb2) binding site had been mutated are able to fully rescue the growth defects of *chico* flies (OLDHAM *et al.* 2002). Therefore it is currently unclear whether the InR activates MAPK signalling in *Drosophila* (BATEMAN and MCNEILL 2006).

In the current study we find that differentiation is temporally regulated by TOR and S6K, but not by 4EBP or eIF4E, thus providing the first branch in the differentiation pathway downstream of InR signalling in the eye. We also show that activation of the InR/TOR pathway regulates the expression, at the transcriptional level, of the EGFR pathway components Argos, rhomboid (rho) and pointedP2 (pntP2). Moreover, reducing the level of EGFR signalling, by using a *pntP2* hypomorphic allele, causes a cell-type specific delay in differentiation which is identical to that in mutants which inhibit the InR/TOR pathway. Finally we show that the EGFR and InR/TOR pathways genetically interact in controlling the timing of PR differentiation.

Materials and Methods

To generate loss-of-function clones, 48-72 hour-old larvae were heat-shocked for 1-2 hours at 37°C. Over-expression clones were generated using the ‘flip-out’ technique (Neufeld et al., 1998), where 48-60 hour-old larvae were heat-shocked for 2.5 hours at 37°C. Third instar eye discs were fixed in PBSA/4% formaldehyde (EMS scientific) for 45 minutes, washed in PBSA/0.1% TritonX100 (Sigma) and incubated overnight with primary antibody. Primary antibodies were used as follows: mouse and rabbit anti-GFP (Molecular Probes, 1:1000), rabbit anti-Bar (a gift from Dr Saigo, 1:200), mouse anti-Prospero (DHSB, 1:10), guinea pig anti-Senseless (a gift from H. Bellen, 1:1000), mouse anti-β-galactosidase (Roche, 1:1000), rabbit anti-Spalt (a gift from R. Barrio, 1:500), mouse anti-Rough (DSHB, 1:100), mouse anti-Cut (DSHB, 1:20), mouse anti-Argos (DSHB, 1:100). Secondary antibodies were from Jackson

Laboratories. After staining discs were mounted in Vectastain (Vector Laboratories) and analysed with a Zeiss confocal microscope or a Zeiss Apotome. Three clones for each genotype were quantified using ImageJ and the ratio of mutant clone to twin-spot size calculated.

Drosophila strains

The following stocks were kindly provided to us: The *pten* flies were from Sally Leever and *tsc1* flies from Nic Tapon. The *s6k*, *tsc2* stock was from DJ Pan. The *Rheb* stocks were from Ernst Hafen. The UAS-4EBP stock was from Nahum Sonenberg. *pnt* stocks were from Christian Klämbt. The *rho*^{X81} stock was from Matthew Freeman. *eIF4E* (11720), *aos*^{W11} (2513) and *TOR* (7014) mutants were from The Bloomington Stock Center. Genotypes for generating clones were as follows:

tsc1, *Rheb* mutant clones: *y, w, hs-flp; FRT82, dRheb*^{2D1}, *tsc1*^{2G3}/FRT82B, Ubi-GFP

tsc2 mutant clones: *y, w, hs-flp; gig*⁵⁶, FRT80/FRT80, Ubi-GFP

tsc2 mutant clones with *pntP2-LacZ*: *y, w, hs-flp; gig*⁵⁶, FRT80, *pnt*¹²⁷⁷/FRT80, Ubi-GFP

s6k mutant clones: *y, w, hs-flp; s6k*¹¹, FRT80B/ FRT80, P{LacW}RpL14, eGFP

s6k,tsc2 mutant clones: *y, w, hs-flp; gig*¹⁹², *s6k*¹¹ FRT80//FRT80, Ubi-GFP

eIF4E mutant clones: *y, w, hs-flp; eIF4E*⁰⁷²³⁸, FRT80/ FRT80, arm-LacZ or *y, w, hs-*

flp; *eIF4E*^{715/13}, FRT80/ FRT80, arm-LacZ

eIF4E,tsc2 mutant clones: y, w, *hs-flp*; *eIF4E*⁰⁷²³⁸, *gig*⁵⁶, FRT80/ FRT80,
P{LacW}RpL14, eGFP

4EBP overexpression clones: y, w, *hs-flp*; UAS-4EBP/act>y>Gal4, UAS-GFP

tsc1 mutant clones: y, w, *hs-flp*; *tsc1*^{Q87X}, FRT82B/FRT82B, Ubi-GFP

Rheb mutant clones: *hs-flp*; *Rheb*^{2D1}, FRT82/82FRT, Ubi-GFP, M[95A], Rps63

pten mutant clones: y, w, *hs-flp*; *pten*¹, FRT40/FRT40, Ubi-GFP

pten mutant clones with aos-LacZ: y, w, *hs-flp*; *pten*¹, FRT40/FRT40, Ubi-GFP;
aos^{W11/+}

Rheb mutant clones with aos-LacZ: *hs-flp*; *aos*^{W11}, *Rheb*^{2D1}, FRT82/82FRT, Ubi-GFP,
M[95A], Rps63

pten mutant clones with rho-LacZ: y, w, *hs-flp*; *pten*¹, FRT40/FRT40, Ubi-GFP;
rho^{X81/+}

pten mutant clones with pntP2-LacZ: y, w, *hs-flp*; *pten*¹, FRT40/FRT40, Ubi-GFP;
pnt^{1277/+}

TOR mutant clones: *y, w, hs-flp; TOR^{ΔD}, FRT40A/FRT40, Ubi-GFP; pnt¹²⁷⁷/+*

pntP2 hypomorph clones: *y, w hs-flp; FRT82, pnt¹²³⁰/FRT8, Ubi-GFP*

Rheb, pntP2 mutant clones: *hs-flp; pnt¹²³⁰, Rheb^{2D1}, FRT82/82FRT, Ubi-GFP, M[95A], Rps63*

UAS-Dp110, *pntP2* clones: *hs-flp, UAS-GFP; UAS-Dp110; tub-Gal80, FRT82, pnt¹²³⁰/FRT82, tub-Gal80*

UAS-*pntP2* clones: *hs-flp; act>y>Gal4, UASGFP; UAS-*pntP2**

EGFR^{ACT} clones: *hs-flp; act>y>Gal4, UASGFP; UAS-EGFR^{ACT}*

Results

The InR controls differentiation through a pathway including TOR and S6K, but not 4EBP/eIF4E.

We have shown previously that *tsc1* loss-of-function (LOF) clones cause precocious differentiation of PRs in the developing eye (BATEMAN and MCNEILL 2004). TSC1, together with TSC2, functions as a GAP for the small GTPase Rheb. We found that loss of *Rheb* causes a strong delay in differentiation suggesting that TSC1/2 acts upstream of Rheb in controlling differentiation as it does in growth (SAUCEDO *et al.*

2003; ZHANG *et al.* 2003). However, TSC1 has targets other than Rheb and can activate RhoGTPase and inhibit Rac1 through interaction with the ERM family of actin binding proteins (ASTRINIDIS *et al.* 2002; GONCHAROVA *et al.* 2004; LAMB *et al.* 2000). Therefore we asked whether TSC1 is able to affect differentiation independently of Rheb. To do this we generated *Rheb,tsc1* double mutant clones and observed the differentiation phenotype by staining with anti-Prospero (XU *et al.* 2000). If Rheb is absolutely required for regulation of differentiation by TSC1 then *Rheb,tsc1* double mutant clones should have a similar phenotype to *Rheb* clones. Alternatively, if the TSC1/2 complex is able to regulate differentiation independent of Rheb, then the delayed differentiation phenotype caused by loss of Rheb should be abrogated in *Rheb,tsc1* clones. *Rheb,tsc1* double mutant clones show a strong delay in differentiation (Fig. 1B), similar to that seen in *Rheb* clones (Fig. 2C,D). This result suggests that the primary target of TSC1/2 in controlling the timing of neuronal differentiation is Rheb.

The TSC1/2 complex and Rheb regulate TOR (LEEVEERS and HAFEN 2004). TOR is part of the TORC1 complex, controls growth by phosphorylation of S6K and 4EBP, which in turn affect translation and ribosome biogenesis by regulating Rps6 and eIF4E respectively (INOKI and GUAN 2006; WULLSCHLEGER *et al.* 2006). We asked whether S6K and 4EBP are also able to control neuronal differentiation. *s6k* LOF clones do cause a slight delay in differentiation (Fig. 1C), which is much weaker than the delay seen in *Rheb* or *TOR* LOF clones (Fig. 2C,D; (BATEMAN and MCNEILL 2004). To determine whether S6K mediates the precocious differentiation phenotype seen in *tsc2* clones (Fig. 1D) we generated *s6k,tsc2* double mutant clones. These clones have a

wild-type differentiation phenotype (Fig. 1E), indicating that S6K acts either downstream or in parallel to TSC2 in controlling differentiation.

TOR also controls growth via the translation initiation factor eIF4E and its inhibitory binding partner 4EBP. Homozygous *eIF4E* Drosophila arrest growth during larval development (LACHANCE *et al.* 2002). Lachance *et al.* (2002) however did not determine whether *eIF4E* mutant cells have a growth defect. To assess this we made LOF clones of cells using either weak (*eIF4E*⁰⁷²³⁸) or strong (*eIF4E*^{715/13}) *eIF4E* alleles. Clones made using *eIF4E*⁰⁷²³⁸ had a mild but significant growth defect (mean clone size = 67% ± 1% size of twin-spot, n=3; supplemental fig. 1), while clones made using *eIF4E*^{715/13} had a severe growth defect (Fig. 1F; mean clone size = 8.7% ± 2% size of twin-spot, n=3). Surprisingly, neither the *eIF4E*⁰⁷²³⁸ (supplemental fig. 1) nor *eIF4E*^{715/13} LOF clones have any effect on differentiation in posterior (Fig. 1F) or anterior clones closer to the MF (Fig. 1G). Also, *eIF4E*⁰⁷²³⁸,*tsc2* mutant clones have a similar strong precocious differentiation phenotype to *tsc2* clones (supplemental fig. 1), further suggesting that *eIF4E* is not required for InR/TOR-dependent control of PR differentiation. We also analysed the differentiation phenotype of the eIF4E inhibitory binding partner 4EBP. In accordance with our results with *eIF4E*, overexpression of *4EBP* also has no effect on differentiation (Fig. 1H). In addition, we do not observe any differentiation phenotype in clones of wild-type cells generated in a background heterozygous for a ribosomal subunit dominant mutation (a *Minute* mutant; data not shown), confirming that alteration of the overall translation rate does not affect differentiation. Taken together these data suggest that the control of the timing of neuronal differentiation is regulated by S6K and is independent of 4EBP/eIF4E, while growth is controlled by both these factors.

InR/TOR signalling controls the timing of the differentiation of a subset of photoreceptors

Each ommatidium in the *Drosophila* eye consists of eight photoreceptor (PR) neurons and twelve accessory cells. We have shown that the InR/TOR pathway controls the timing of differentiation of PRs 1,6,7 and cone cells, but does not affect PR 8 (BATEMAN and MCNEILL 2004). The differentiation of PR 8 is followed by the sequential differentiation of PRs 2/5, then PRs 3/4 and finally PRs 1,6 and 7 (Fig. 1A). To determine whether the differentiation of PRs 2-5 is also regulated by the InR/TOR pathway we used antibodies against the transcription factors Rough (KIMMEL *et al.* 1990) and Spalt (BARRIO *et al.* 1999) to analyse the differentiation of PRs 2/5 and 3/4 respectively. If InR/TOR signalling does regulate the differentiation of PRs 2-5 we would expect activation of the pathway by loss of *tsc1* to cause precocious differentiation of these PRs. Both Rough and Spalt staining appeared normal within *tsc1* clones (Fig. 2B and data not shown), suggesting that the InR/TOR pathway does not affect the timing of differentiation of PRs 2/5 or PRs 3/4.

We were concerned that since PRs 2/5 and 3/4 differentiate close to the morphogenetic furrow (rows 3 and 4 respectively, Fig. 1A), that it might be difficult to resolve cells which are precociously differentiating. To overcome this issue we made *Rheb* LOF clones to determine whether there is any delay in the differentiation of PR 2-5 when InR/TOR signalling is inhibited. Differentiation of PRs 1,6,7 and cone cells is strongly delayed in *Rheb* clones (Fig. 2C,D and (BATEMAN and MCNEILL 2004), however, both

Rough (PRs 2,5) and Spalt (PRs 3,4) staining is unaffected in these clones (Fig. 2E,F). Therefore temporal control of differentiation by the InR/TOR pathway in the developing eye is stage/cell type specific: the late differentiating PRs 1,6,7 and cone cells are dependent on the InR/TOR pathway, while the early differentiating PRs 2-5 and 8 are independent of InR/TOR signalling.

Transcription of Argos, a reporter of EGFR signalling activity, is regulated by the InR/TOR pathway

The stage/cell type-specific nature of the temporal control of differentiation suggests that the InR/TOR pathway achieves this regulation through a novel mechanism. To investigate this we asked whether any of the pathways known to be important for PR differentiation are affected by changes in InR/TOR signalling. Since the passage of the MF is unaffected by the InR/TOR pathway it seemed unlikely that Dpp, Hh or Wingless signalling were being affected. Next we asked whether EGFR signalling is regulated by the InR/TOR pathway in the developing eye. We had previously analysed EGFR signalling activity in two ways. First we stained with an antibody against dual phosphorylated MAPK (dpERK), which gives a direct readout of EGFR signalling levels (GABAY *et al.* 1997). Second we analysed the level of the ETS protein Yan, whose accumulation in the nucleus is dependent on its phosphorylation state and hence the level of EGFR activity (SONG *et al.* 2005; TOOTLE *et al.* 2003). Neither dpERK nor Yan staining are affected by activation of InR/TOR signalling (BATEMAN and MCNEILL 2004). However, we had not tested whether EGFR signalling is being affected downstream or in parallel to MAPK and Yan.

To test whether there is any overall activation of EGFR signalling by the InR/TOR pathway we looked at the expression of Argos. Argos is a secreted protein that functions as an inhibitory ligand of the EGFR (FREEMAN *et al.* 1992b). *argos* expression is induced by EGFR activation in differentiating cells and is thought to result in a feedback loop which inhibits the differentiation of surrounding cells (GOLEMBO *et al.* 1996). As a consequence of its dependence on EGFR activation Argos is strongly expressed in developing PRs as they differentiate (FREEMAN *et al.* 1992b). To analyse the expression of Argos in cells in which InR/TOR signalling is activated we stained *pten* LOF clones with an Argos monoclonal antibody. Although Argos stains poorly in imaginal discs we see a consistent increase in Argos accumulation in *pten* clones (Fig. 3A).

Next we asked whether the ability of the InR/TOR pathway to modulate Argos levels is caused by changes in *argos* gene expression. This result would indicate that EGFR signalling is being affected, rather than a stabilisation of Argos post-transcriptionally. To address this we used the *argos*^{W11} lacZ reporter line (Freeman 1992). Using *argos*^{W11} we observed a strong increase in *argos* expression in *pten* LOF clones (Fig. 3B). Interestingly, in *pten* clones that cross the MF strong precocious expression of *argos* is seen in the mutant cells (Fig. 3B). To determine whether inhibition of the InR/TOR pathway can regulate *argos* expression we generated *Rheb* clones in larvae carrying the *argos*^{W11} allele. Loss of *Rheb* causes a strong decrease in *argos* expression in differentiating cells (Fig. 3C). Thus both positive and negative regulators of the InR/TOR signaling pathway lead to alterations in *argos* expression.

Since Argos is also an inhibitory ligand of the EGFR (FREEMAN *et al.* 1992b), we analysed the expression of *rhomoid-1* (*rho*) as an independent readout of EGFR activity. *rho* expression was monitored using the X81 enhancer trap line which is expressed strongly in PRs 2/5 and 8 (FREEMAN *et al.* 1992a). In accordance with the *argos* data, *rho* expression is up-regulated in *pten* LOF clones (Fig. 3D). These changes appear to be specific since the expression of several other cell fate genes is unaffected by changes in InR/TOR signalling (BATEMAN and MCNEILL 2004) including the Notch ligand Delta (Supplemental fig. 3). In conclusion, these data suggest that there is cross-talk between InR/TOR signalling and the EGFR pathway and that this occurs downstream of MAPK.

Expression of pntP2 is regulated by InR/TOR signalling

argos expression is activated by the ETS transcription factor *pointed* (*pnt*). *pnt* is expressed as two alternatively spliced isoforms, P1 and P2, which share a C-terminal region that contains the ETS motif (SCHOLZ *et al.* 1993). *pntP2* is expressed specifically in the embryonic midline glial cells (KLAMBT 1993), and *argos* expression is lost in these cells in *pointed* (*pnt*) mutant embryos (SCHOLZ *et al.* 1997). Activation of the EGFR results in phosphorylation of MAPK which enters the nucleus and phosphorylates *pntP2* (BRUNNER *et al.* 1994; O'NEILL *et al.* 1994). In the eye imaginal disc *pntP2* is expressed in precursor cells posterior to the MF and in PRs 1,6,7 and cone cells (BRUNNER *et al.* 1994). Since *argos* is a transcriptional target of *pntP2* we wondered whether *pntP2* expression might also be regulated by InR/TOR signalling. To test whether *pntP2* expression is regulated by InR/TOR signalling we used the *pnt*¹²⁷⁷

allele which contains a P{LacW}-element within the first, non-coding, exon of *pntP2* (SCHOLZ *et al.* 1993). Using *pnt*¹²⁷⁷ we observe a strong increase in *pntP2* expression in *pten* LOF clones (Fig. 4A). Interestingly, the increase in *pntP2* expression differs spatio-temporally across the field of differentiating cells. *pntP2* expression is increased most strongly in cells as they differentiate, but this increase is lost once the cells become more mature. Moreover, dramatic precocious expression of *pntP2* is observed in *pten* clones that span the MF (Fig. 4A). Importantly, *pntP2* expression is also up-regulated in undifferentiated cells around the MF, suggesting that the increase in expression is not simply an indirect consequence of the precocious differentiation of PRs. We also observe a similar upregulation of *pntP2* expression in clones that have activated InR/TOR signalling due to loss of *tsc2* (Fig. 4B). The increase in *pntP2* expression are not a result of a general increase in transcription due to increased growth, since we do not see increased expression of several other markers of PR cell fate ((BATEMAN and MCNEILL 2004). To examine the effect of blocking InR/TOR signalling we examined *pntP2* expression in cells mutant for *TOR*. LOF clones of *TOR* show decreased expression of *pntP2* (Fig. 4C). Therefore *pntP2* expression is sensitive to both activation and inhibition of InR/TOR signalling. To determine whether this property is specific to the eye we looked at *pntP2* expression in *pten* clones in the leg and eye discs. We did not observe any change in *pntP2* expression in these clones (Supplemental fig. 2), suggesting either that InR/TOR regulation of *pntP2* is specific to the developing eye (perhaps requiring specific factors expressed close to the MF), or that the spatio-temporal nature of eye development in *Drosophila* makes it possible to observe changes that cannot be seen in other imaginal discs.

Reducing EGFR signalling phenocopies loss of Rheb or TOR in developing PRs.

Argos, *rho* and *pntP2* expression levels are all regulated by InR/TOR signalling suggesting cross-talk between InR/TOR and EGFR pathways. However, complete loss of EGFR or *pntP2* activity (using null alleles) completely *blocks* the differentiation of all PRs except PR 8 (data not shown; (BAONZA *et al.* 2001; BAONZA *et al.* 2002; YANG and BAKER 2003), whereas inhibition of the InR/TOR pathway causes a *delay* only in the differentiation of PRs 1,6,7 and cone cells (Fig. 2). To reconcile these observations we wondered whether a reduction, rather than a complete loss in EGFR activity would cause the same cell-type specific delay in differentiation as inhibition of the InR/TOR pathway.

To determine the affect of reducing EGFR signalling levels we used a hypomorphic allele of *pntP2* (*pntP2*¹²³⁰), which was generated by the imprecise excision of a P-element in the first, non-coding, exon of *pntP2* (KLAMBT 1993). We stained *pntP2*¹²³⁰ clones with the same panel of markers that we had used to analyse the differentiation phenotype of InR/TOR pathways mutants (Fig. 2). Interestingly the PR differentiation phenotype in *pntP2*¹²³⁰ clones is identical to that in *Rheb* or *TOR* LOF clones (compare Fig. 5 to Fig. 2). Specifically, PR 8 (stained for Senseless expression; Fig. 5A), PRs 2/5 (stained for Rough expression; Fig. 5B) and PRs 3/4 (stained for Spalt expression; Fig. 5C) differentiate normally in *pntP2*¹²³⁰ clones. In contrast the differentiation of PRs 1,6 (stained for Bar expression; Fig. 5D), PR 7 (stained for Prospero expression; Fig. 5E) and cone cells (stained for Prospero expression Fig. 5E and Cut expression Fig. 5F) are strongly delayed but not completely blocked. The phenotypic similarity between PRs with reduced EGFR signalling and PRs in which InR/TOR signalling is inhibited is

consistent with InR/TOR signalling modulating EGFR transcriptional outputs to control neuronal differentiation.

InR/TOR and EGFR signalling interact genetically

Since reducing EGFR pathway activity through *pntP2* phenocopied inhibition of the InR/TOR pathway we wondered whether these two pathways could interact genetically. To test this we generated clones that were double mutant for *pntP2*¹²³⁰ and *Rheb*^{2D1}. Inhibition of differentiation in these clones (Fig. 6B) was much more severe than in *pntP2* (or *Rheb*) single mutant clones (Fig. 6A). *pntP2*¹²³⁰, *Rheb*^{2D1} double mutant clones block rather than delay the differentiation of PRs 1,6 (Fig. 6B).

Conversely, when we overexpressed Dp110 in *pnt*¹²³⁰ clones using the MARCM technique (LEE and LUO 1999), the delay in the differentiation of PRs 1,6 was much less severe (Fig. 6D) than in *pnt*¹²³⁰ clones alone (Fig. 6C) and the precocious differentiation normally seen with Dp110 overexpression was completely suppressed, strongly suggesting that *pntP2* acts downstream of Dp110. These data demonstrate that the InR/TOR and EGFR pathways can interact genetically and are consistent with the regulation of neuronal differentiation by the InR/TOR through modulation of EGFR transcriptional output.

Discussion

Tight coordination of growth and differentiation is essential for normal development.

We have previously shown that InR/TOR signalling controls the timing of neuronal

differentiation (BATEMAN and MCNEILL 2004) in the eye and leg in *Drosophila*. Here we demonstrate that the InR/TOR pathway regulates neuronal differentiation in an S6K dependent, but 4EBP/eIF4E independent manner. Previously we were unable to determine whether InR/TOR signalling was acting downstream or in parallel to the EGFR/MAPK pathway. Using *argos* and *rho* as reporters we have shown that the InR/TOR pathway is able to regulate EGFR/MAPK signalling downstream of MAPK. Moreover, *pntP2* expression is up and down-regulated by activation or inhibition of InR/TOR signalling respectively and InR/TOR and EGFR pathways interact through *pntP2*. Taken together our data suggest that temporal control of differentiation by the InR/TOR pathway is achieved by modulation of EGFR pathway transcriptional targets in differentiating PRs.

TOR is part of two multimeric complexes (TORC1 and TORC2) and is a core component of the InR pathway (INOKI and GUAN 2006; WULLSCHLEGER *et al.* 2006). TORC1 activity is regulated by nutrient and energy levels (HARA *et al.* 1998; INOKI *et al.* 2003) providing a conduit for hormonal and catabolic cellular inputs. Growth is regulated by two downstream targets of TORC1: S6K and 4EBP. Our data demonstrate that upstream of TORC1, differentiation and growth are regulated by the same factors. Downstream of TORC1, differentiation and growth differ significantly in that loss of *s6k*, but not *eIF4E* (or overexpression of 4EBP) affects differentiation. eIF4E regulates 7-methyl-guanosine cap dependent translation and is the rate-limiting factor in translation initiation (RICHTER and SONENBERG 2005). Our finding that eIF4E does not affect differentiation suggests that the temporal control of differentiation is not based on a translation initiation-dependent mechanism. Strikingly, we show that loss of *s6k* blocks the precocious differentiation induced by loss of *tsc2*. Given the relatively

weak effects of loss of *s6k* this may seem surprising. However, the degree of suppression is similar to the affect of loss of *s6k* on the over-growth phenotype caused by loss of *tsc2*: namely *tsc2,s6k* double mutant cells are the same size as wild-type cells (GAO *et al.* 2002). Although loss of *eIF4E* has no affect on differentiation it may act redundantly with another factor. The *Drosophila* genome contains eight different *eIF4E* isoforms (HERNANDEZ *et al.* 2005) and it will be interesting in future to test whether any of these isoforms regulate differentiation, or alternatively whether *eIF4E* and *s6k* act redundantly. Although further work is required to determine the precise relationship between S6K and the InR/TOR pathway, our data point to a critical role of S6K in coordinating neuronal differentiation and growth.

As in other neuronal systems, differentiation of PRs in the *Drosophila* eye occurs in a stereotyped manner. The advantage of the *Drosophila* retina as an experimental system is that the PRs differentiate spatio-temporally. Using this feature, as well as a series of cell-type specific antibodies, we have demonstrated that InR/TOR signalling is selective in the cell-types that it affects. The differentiation of PRs 2/5, 3/4 and 8 are unaffected by perturbations in InR/TOR signalling, whereas PRs 1,6,7 and cone cells are dependent on this pathway for temporal control of differentiation. Interestingly the affected cells all differentiate after the second mitotic wave. However, we have shown that regulators of the cell cycle do not affect the temporal control of differentiation (BATEMAN and MCNEILL 2004). Why then are PRs 1,6,7 and cone cells specifically affected? In cells with increased InR/TOR signalling, the expression of *argos*, *rho* and *pntP2* is precocious and increased throughout the clone, suggesting that the upregulation of EGFR signalling occurs in all cells. However, decreasing EGFR activity using a hypomorphic *pntP2* allele specifically affects the differentiation of PRs

1,6,7 and cone cells. Interestingly, *pntP2* expression in differentiated cells is also restricted to PRs 1,6,7 and cone cells. These observations suggest that differentiation of PRs 1,6,7 and cone cells is critically dependent on EGFR levels signalling through *pntP2*. Therefore, although activation of InR/TOR signalling causes upregulation of EGFR transcriptional targets in all cells as they differentiate, the phenotypic effect is only seen in PRs 1,6,7 and cone cells since these cells are highly sensitive to EGFR activity signalling through *pntP2*. This possibility is supported by the fact that precocious differentiation caused by overexpression of Dp110 can be suppressed by the simultaneous reduction of *pntP2* levels (Fig. 6). It has been suggested that later differentiating PRs require higher levels of EGFR activity and R7 requires activation of both EGFR and Sevenless RTKs (FREEMAN 1996). In the case of InR/TOR pathway activation it may be that the ‘second burst’ of RTK activity is enhanced causing PRs 1,6,7 and cone cells to differentiate precociously. There maybe other as yet unidentified factors through which the InR/TOR pathway controls the expression of Aos and rho in PRs 2-5 and 8.

Activation of insulin and insulin like growth factor receptors in mammalian systems is well known to elicit a response via the Ras/MAPK pathway (BALTENSBERGER *et al.* 1993; DOWNWARD 2003; SKOLNIK *et al.* 1993). However, loss of the *InR* in the *Drosophila* eye does not result in a loss of PRs, a hallmark of the Ras pathway (BROGIOLO *et al.* 2001), nor does mutation of the putative Drk binding site in *chico* affect the function of the *Drosophila* IRS (OLDHAM *et al.* 2002). In accordance with these data we do not observe any change in dpERK staining when the InR/TOR pathway is activated the eye disc. Rather than a direct activation of Ras signalling by the InR, our data suggest that in the developing eye cross-talk between these pathways

occurs at the level of regulation of the expression of EGFR transcriptional outputs. The most proximal component of the EGFR pathway that is regulated by InR/TOR signalling is *pntP2*. However, our data suggest that temporal control of PR differentiation requires concerted regulation of EGFR transcriptional outputs, since overexpression of *pntP2* alone is not sufficient to cause precocious differentiation, whereas overexpression of activated-EGFR is sufficient (supplemental fig. 4). Interestingly, microarray analyses of *Drosophila* and human cells has shown that the InR/TOR pathway regulates the expression of hundreds of genes (GUERTIN *et al.* 2006a; PENG *et al.* 2002). The mechanism by which this transcriptional control is exerted has yet to be elucidated. It will be interesting in future to determine the extent of transcriptional cross-talk between InR/TOR and EGFR pathways in developing neurons.

Acknowledgements

We gratefully acknowledge the generous gifts of antibodies or fly stocks from Sally Leever, Nic Tapon, Hugo Bellen, Ernst Hafen, DJ Pan, Nahum Sonenberg, Christian Klämbt, Frank Pichaud and Matthew Freeman. This work was supported by Cancer Research UK, the USA Department of Defense, and the Tuberous Sclerosis Alliance.

Figure legends

Figure 1. *InR* and *TOR* signalling act through *S6K*, but not *eIF4E* to control the timing of neuronal differentiation. (A) Schematic showing the spatiotemporal nature of PR

differentiation in the *Drosophila* eye imaginal disc. MF: morphogenetic furrow. (B and B') *tsc1^{2G3},Rheb^{2D1}* double mutant clones have an identical delay in differentiation (stained for Prospero expression, shown in red) to *Rheb^{2D1}* clones (Fig. 2C). (C and C') Loss of *S6k* causes a slight delay in the differentiation of PR 7 and cone cells (stained for Bar expression, shown in red). (D and D') *tsc2 (gig⁵⁶)* clones cause precocious differentiation of PRs 1,6 (stained for Bar expression, shown in red). (E and E') The precocious differentiation phenotype of *tsc2* cells is suppressed in *tsc2(gig¹⁹²),s6k¹¹* clones (Bar staining in red). (F-G) *eIF4E^{715/13}* LOF clones (F and F') have a do not delay differentiation and precocious differentiation still occurs in *eIF4E⁰⁷²³⁸,tsc2(gig⁵⁶)* double mutant LOF clones (G and G'), (Bar staining in red). (H and H') overexpression of 4EBP (shown by the presence of GFP staining) does not have any affect on differentiation of PRs 1,6 (stained for Bar expression, shown in red). LOF clones in panels B-G are marked by the loss of GFP (shown in green). Anterior is to the left in all panels.

Figure 2. *InR/TOR* signalling controls the differentiation of specific cell types in the developing eye. (A and A') Cells mutant for *tsc1(tsc1^{Q87X})* show precocious differentiation of PRs 1,6 (stained for Bar expression, shown in red) ahead of the wild-type differentiation front, arrow indicates an example of a precociously differentiated PR. (B and B') Differentiation of PRs 3/4 (stained for Spalt expression, shown in red) is unaffected in *tsc1^{Q87X}* clones. (C-D) Differentiation of PRs 1,6 (stained for Bar expression, shown in red in C and C') and cone cells (stained with Cut, shown in red in D and D') is strongly delayed in *Rheb^{2D1}* clones. (E-F) PR 2/5 (stained for Rough expression, shown in red in E and E') and PR 3/4 (stained for Spalt expression, shown

in red in F and F') differentiation is unaffected in *Rheb*^{2D1} clones. LOF clones in all panels are marked by the loss of GFP staining (shown in green). Anterior is to the left in all panels.

Figure 3. *argos* and *rho* expression is regulated by InR/TOR signalling in developing neurons. (A and A') The level of Argos protein (detected using an anti-Argos monoclonal antibody, shown in red) is increased in *pten*¹ mutant cells (marked by loss of GFP staining). Note how Argos staining is seen ahead of the normal expression front (marked with an arrow). (B-C) *argos* expression is regulated by InR/TOR signalling at the level of transcription. Expression of β -galactosidase (stained with an anti- β -galactosidase antibody, shown in red) from the P{lwB}-element insertion in *argos* (*aos*^{w11}) is upregulated in *pten*¹ clones (B and B') and downregulated in *Rheb*^{2D1} clones (C and C'). (D and D') *rho* expression (using the *rho*^{X81} reporter, detected by staining with a anti- β -galactosidase antibody, shown in red) is upregulated in *pten*¹ clones. Clones are marked by loss of GFP staining and anterior is to the left in all panels.

Figure 4. *pntP2* expression is regulated by InR/TOR signalling. (A-B) *pntP2* transcription, detected by staining for β -galactosidase in flies carrying a P{LacW}element in *pntP2* (*pnt*¹²⁷⁷), is up-regulated and precocious in *pten*¹ (A and A') and *tsc2*(*gig*⁵⁶) clones (B and B'). Note that the disc shown in B is a younger disc and so *pntP2* is upregulated more posteriorly. Conversely *pntP2* transcription is down-regulated in *TOR*^{AD} clones (C and C'). LOF clones in A-C are marked by the loss of GFP staining (shown in green). Anterior is to the left in all panels.

Figure 5. Reducing EGFR signalling phenocopies the differentiation phenotype of loss of *Rheb* or *TOR*. *pntP2* hypomorphic clones made using the allele *pntP2*¹²³⁰ show cell type specific delays in PR differentiation identical to those seen in LOF clones of positive effectors of InR/TOR signalling such as *Rheb* and *TOR*. (A-C) *pntP2*¹²³⁰ clones have no effect on the differentiation of PR 8 (stained for Senseless expression, shown in red in A and A'), PRs 2/5 (stained for Rough expression, shown in red in B and B') or PRs 3/4 (stained for Spalt expression, shown in red in C and C'). Note that Spalt staining shows a delay towards the posterior of the disc where the antibody also stains PRs 1,6. In contrast *pntP2*¹²³⁰ clones show a strong delay in the differentiation of PRs 1,6 (stained for Bar expression, shown in red in D and D'), PR 7 (stained for Prospero expression, which is also expressed in cone cells, shown in red in E and E') and cone cells (stained for Cut expression, shown in red in F and F' and Prospero expression, shown in red in E and E'). LOF clones in all panels are marked by the loss of GFP staining (shown in green). Anterior is to the left in all panels.

Figure 6. *InR/TOR* and *EGFR* signalling interact genetically. (A-B) Differentiation of PRs1,6 is delayed in *pnt*¹²³⁰ clones (A and A') and blocked in *pnt*¹²³⁰,*Rheb*^{2D1} clones (B and B'). (C-D) Using the MARCM system differentiation of PRs1,6 is delayed in *pnt*¹²³⁰ clones (C and C'), whereas the delay is significantly weaker in *pnt*¹²³⁰ clones overexpressing Dp110 (D and D'). Mutant cells are marked by the absence of GFP in (A) and (B), but by the presence of GFP in (C) and (D). PRs1,6 are shown by Bar stained (red) in all panels.

Supplemental figure 1. *eIF4E*⁰⁷²³⁸ LOF clones (A and A') do not delay differentiation and precocious differentiation still occurs in *eIF4E*⁰⁷²³⁸,*tsc2(gig*⁵⁶) double mutant LOF clones (B and B'). Mutant cells are marked by the absence of GFP, Bar staining in red.

Supplemental figure 2. *pntP2* expression is unaffected in *pten*¹ LOF clones in the leg (A and A') or wing (B and B') imaginal discs. *Pnt*¹²⁷⁷ expressed detected by staining discs stained for β -galactosidase expression (red), mutant cells are marked by the absence of GFP.

Supplemental figure 3. Expression of Delta is unaffected in *pten*¹ LOF clones. Delta staining shown in red, mutant cells are marked by the absence of GFP.

Supplemental figure 4. Overexpression of *pntP2* (A and A') has no affect in differentiation, whereas overexpression of activated EGFR (B and B') causes precocious differentiation of PRs 1,6 (arrowhead). Bar staining shown in red, mutant cells are marked by the absence of GFP.

References

- ASTRINIDIS, A., T. P. CASH, D. S. HUNTER, C. L. WALKER, J. CHERNOFF *et al.*, 2002
Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. *Oncogene* **21**: 8470-8476.
- BALTENSPERGER, K., L. M. KOZMA, A. D. CHERNIACK, J. K. KLARLUND, A. CHAWLA *et al.*, 1993 Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes. *Science* **260**: 1950-1952.
- BAONZA, A., T. CASCI and M. FREEMAN, 2001 A primary role for the epidermal growth factor receptor in ommatidial spacing in the *Drosophila* eye. *Curr Biol* **11**: 396-404.

- BAONZA, A., C. M. MURAWSKY, A. A. TRAVERS and M. FREEMAN, 2002 Pointed and Tramtrack69 establish an EGFR-dependent transcriptional switch to regulate mitosis. *Nat Cell Biol* **4**: 976-980.
- BARRIO, R., J. F. DE CELIS, S. BOLSHAKOV and F. C. KAFATOS, 1999 Identification of regulatory regions driving the expression of the *Drosophila* spalt complex at different developmental stages. *Dev Biol* **215**: 33-47.
- BATEMAN, J. M., and H. MCNEILL, 2004 Temporal control of differentiation by the insulin receptor/tor pathway in *Drosophila*. *Cell* **119**: 87-96.
- BATEMAN, J. M., and H. MCNEILL, 2006 Insulin/IGF signalling in neurogenesis. *Cell Mol Life Sci* **63**: 1701-1705.
- BRENNAN, C. A., and K. MOSES, 2000 Determination of *Drosophila* photoreceptors: timing is everything. *Cell Mol Life Sci* **57**: 195-214.
- BRITTON, J. S., W. K. LOCKWOOD, L. LI, S. M. COHEN and B. A. EDGAR, 2002 *Drosophila*'s insulin/PI3-kinase pathway coordinates cellular metabolism with nutritional conditions. *Dev Cell* **2**: 239-249.
- BROGIOLO, W., H. STOCKER, T. IKEYA, F. RINTELEN, R. FERNANDEZ *et al.*, 2001 An evolutionarily conserved function of the *Drosophila* insulin receptor and insulin-like peptides in growth control. *Curr Biol* **11**: 213-221.
- BRUNNER, D., K. DUCKER, N. OELLERS, E. HAFEN, H. SCHOLZ *et al.*, 1994 The ETS domain protein pointed-P2 is a target of MAP kinase in the sevenless signal transduction pathway. *Nature* **370**: 386-389.
- CAI, S.-L., A. R. TEE, J. D. SHORT, J. M. BERGERON, K. KIM *et al.*, 2006 Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. *J. Cell Biol.* **173**: 279-289.
- DOWNWARD, J., 2003 Targeting RAS signalling pathways in cancer therapy. *Nat Rev Cancer* **3**: 11-22.
- FREEMAN, M., 1996 Reiterative use of the EGF receptor triggers differentiation of all cell types in the *Drosophila* eye. *Cell* **87**: 651-660.
- FREEMAN, M., 1997 Cell determination strategies in the *Drosophila* eye. *Development* **124**: 261-270.
- FREEMAN, M., B. E. KIMMEL and G. M. RUBIN, 1992a Identifying targets of the rough homeobox gene of *Drosophila*: evidence that rhomboid functions in eye development. *Development* **116**: 335-346.
- FREEMAN, M., C. KLAMBT, C. S. GOODMAN and G. M. RUBIN, 1992b The argos gene encodes a diffusible factor that regulates cell fate decisions in the *Drosophila* eye. *Cell* **69**: 963-975.
- GABAY, L., R. SEGER and B. Z. SHILO, 1997 In situ activation pattern of *Drosophila* EGF receptor pathway during development. *Science* **277**: 1103-1106.
- GAO, X., and D. PAN, 2001 TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. *Genes Dev* **15**: 1383-1392.
- GAO, X., Y. ZHANG, P. ARRAZOLA, O. HINO, T. KOBAYASHI *et al.*, 2002 Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. *Nat Cell Biol* **4**: 699-704.
- GOLEMBO, M., R. SCHWEITZER, M. FREEMAN and B. Z. SHILO, 1996 Argos transcription is induced by the *Drosophila* EGF receptor pathway to form an inhibitory feedback loop. *Development* **122**: 223-230.
- GONCHAROVA, E., D. GONCHAROV, D. NOONAN and V. P. KRYMSKAYA, 2004 TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. *J Cell Biol* **167**: 1171-1182.

- GUERTIN, D. A., K. V. GUNTUR, G. W. BELL, C. C. THOREEN and D. M. SABATINI, 2006a Functional genomics identifies TOR-regulated genes that control growth and division. *Curr Biol* **16**: 958-970.
- GUERTIN, D. A., D. M. STEVENS, C. C. THOREEN, A. A. BURDS, N. Y. KALAANY *et al.*, 2006b Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. *Dev Cell* **11**: 859-871.
- HARA, K., K. YONEZAWA, Q. P. WENG, M. T. KOZLOWSKI, C. BELHAM *et al.*, 1998 Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. *J Biol Chem* **273**: 14484-14494.
- HARRINGTON, L. S., G. M. FINDLAY, A. GRAY, T. TOLKACHEVA, S. WIGFIELD *et al.*, 2004 The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. *J Cell Biol* **166**: 213-223.
- HERNANDEZ, G., M. ALTMANN, J. M. SIERRA, H. URLAUB, R. DIEZ DEL CORRAL *et al.*, 2005 Functional analysis of seven genes encoding eight translation initiation factor 4E (eIF4E) isoforms in *Drosophila*. *Mech Dev* **122**: 529-543.
- INOKI, K., and K. L. GUAN, 2006 Complexity of the TOR signaling network. *Trends Cell Biol* **16**: 206-212.
- INOKI, K., T. ZHU and K. L. GUAN, 2003 TSC2 mediates cellular energy response to control cell growth and survival. *Cell* **115**: 577-590.
- KIMMEL, B. E., U. HEBERLEIN and G. M. RUBIN, 1990 The homeo domain protein rough is expressed in a subset of cells in the developing *Drosophila* eye where it can specify photoreceptor cell subtype. *Genes Dev* **4**: 712-727.
- KLAMBT, C., 1993 The *Drosophila* gene pointed encodes two ETS-like proteins which are involved in the development of the midline glial cells. *Development* **117**: 163-176.
- LACHANCE, P. E., M. MIRON, B. RAUGHT, N. SONENBERG and P. LASKO, 2002 Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth. *Mol Cell Biol* **22**: 1656-1663.
- LAMB, R. F., C. ROY, T. J. DIEFENBACH, H. V. VINTERS, M. W. JOHNSON *et al.*, 2000 The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. *Nat Cell Biol* **2**: 281-287.
- LEE, T., and L. LUO, 1999 Mosaic analysis with a repressible cell marker for studies of gene function in neuronal morphogenesis. *Neuron* **22**: 451-461.
- LEEVERS, S. J., and E. HAFEN, 2004 Growth regulation by insulin and TOR signalling in *Drosophila*, pp. 167-192 in *Cell Growth*, edited by M. N. HALL, R. RAFF and G. THOMAS. Cold Spring NY: Cold Spring Harbour Laboratory Press.
- LONG, X., Y. LIN, S. ORTIZ-VEGA, K. YONEZAWA and J. AVRUCH, 2005 Rheb binds and regulates the mTOR kinase. *Curr Biol* **15**: 702-713.
- NEUFELD, T. P., A. F. DE LA CRUZ, L. A. JOHNSTON and B. A. EDGAR, 1998 Coordination of growth and cell division in the *Drosophila* wing. *Cell* **93**: 1183-1193.
- O'NEILL, E. M., I. REBAY, R. TJIAN and G. M. RUBIN, 1994 The activities of two Ets-related transcription factors required for *Drosophila* eye development are modulated by the Ras/MAPK pathway. *Cell* **78**: 137-147.
- OLDHAM, S., H. STOCKER, M. LAFFARGUE, F. WITTEW, M. WYMAN *et al.*, 2002 The *Drosophila* insulin/IGF receptor controls growth and size by modulating PtdInsP(3) levels. *Development* **129**: 4103-4109.

- PENG, T., T. R. GOLUB and D. M. SABATINI, 2002 The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. *Mol Cell Biol* **22**: 5575-5584.
- POTTER, C. J., H. HUANG and T. XU, 2001 *Drosophila* Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. *Cell* **105**: 357-368.
- RADIMERSKI, T., J. MONTAGNE, M. HEMMINGS-MIESZCZAK and G. THOMAS, 2002 Lethality of *Drosophila* lacking TSC tumor suppressor function rescued by reducing dS6K signaling. *Genes Dev* **16**: 2627-2632.
- RICHTER, J. D., and N. SONENBERG, 2005 Regulation of cap-dependent translation by eIF4E inhibitory proteins. *Nature* **433**: 477-480.
- RUSTEN, T. E., K. LINDMO, G. JUHASZ, M. SASS, P. O. SEGLEN *et al.*, 2004 Programmed autophagy in the *Drosophila* fat body is induced by ecdysone through regulation of the PI3K pathway. *Dev Cell* **7**: 179-192.
- SARBASSOV, D. D., D. A. GUERTIN, S. M. ALI and D. M. SABATINI, 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science* **307**: 1098-1101.
- SAUCEDO, L. J., X. GAO, D. A. CHIARELLI, L. LI, D. PAN *et al.*, 2003 Rheb promotes cell growth as a component of the insulin/TOR signalling network. *Nat Cell Biol* **5**: 566-571.
- SCHOLZ, H., J. DEATRICK, A. KLAES and C. KLAMBT, 1993 Genetic dissection of pointed, a *Drosophila* gene encoding two ETS-related proteins. *Genetics* **135**: 455-468.
- SCHOLZ, H., E. SADLOWSKI, A. KLAES and C. KLAMBT, 1997 Control of midline glia development in the embryonic *Drosophila* CNS. *Mech Dev* **64**: 137-151.
- SCOTT, R. C., O. SCHULDINER and T. P. NEUFELD, 2004 Role and regulation of starvation-induced autophagy in the *Drosophila* fat body. *Dev Cell* **7**: 167-178.
- SHAH, O. J., Z. WANG and T. HUNTER, 2004 Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. *Curr Biol* **14**: 1650-1656.
- SKOLNIK, E. Y., A. BATZER, N. LI, C. H. LEE, E. LOWENSTEIN *et al.*, 1993 The function of GRB2 in linking the insulin receptor to Ras signaling pathways. *Science* **260**: 1953-1955.
- SONG, H., M. NIE, F. QIAO, J. U. BOWIE and A. J. COUREY, 2005 Antagonistic regulation of Yan nuclear export by Mae and Crm1 may increase the stringency of the Ras response. *Genes Dev* **19**: 1767-1772.
- TAPON, N., N. ITO, B. J. DICKSON, J. E. TREISMAN and I. K. HARIHARAN, 2001 The *Drosophila* tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. *Cell* **105**: 345-355.
- TOOTLE, T. L., P. S. LEE and I. REBAY, 2003 CRM1-mediated nuclear export and regulated activity of the Receptor Tyrosine Kinase antagonist YAN require specific interactions with MAE. *Development* **130**: 845-857.
- UM, S. H., F. FRIGERIO, M. WATANABE, F. PICARD, M. JOAQUIN *et al.*, 2004 Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature* **431**: 200-205.
- VOAS, M. G., and I. REBAY, 2004 Signal integration during development: insights from the *Drosophila* eye. *Dev Dyn* **229**: 162-175.
- WOLFF, T., and D. READY, 1993 Pattern Formation in the *Drosophila* Retina, pp. 1277-1326 in *The Development of Drosophila melanogaster*, edited by B. M and M.-A. A. CSHL Press.

- WULLSCHLEGER, S., R. LOEWITH and M. N. HALL, 2006 TOR signaling in growth and metabolism. *Cell* **124**: 471-484.
- XU, C., R. C. KAUFFMANN, J. ZHANG, S. KLADNY and R. W. CARTHEW, 2000 Overlapping activators and repressors delimit transcriptional response to receptor tyrosine kinase signals in the *Drosophila* eye. *Cell* **103**: 87-97.
- YANG, L., and N. E. BAKER, 2003 Cell cycle withdrawal, progression, and cell survival regulation by EGFR and its effectors in the differentiating *Drosophila* eye. *Dev Cell* **4**: 359-369.
- ZHANG, Y., X. GAO, L. J. SAUCEDO, B. RU, B. A. EDGAR *et al.*, 2003 Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. *Nat Cell Biol* **5**: 578-581.















Figure 1

Figure 2




Figure 3




Figure 4




Figure 5











Figure 6





Supplemental Figure 1





Supplemental Figure 2



Supplemental Figure 3



Supplemental figure 4



Visions & Reflections

Insulin/IGF signalling in neurogenesis

J. M. Bateman^{a,*} and H. McNeill^b

^a The Wolfson Centre For Age-Related Disease, Hodgkin Building, King's College London, Guy's Campus, London, SE1 1UL (United Kingdom), Fax: +44 207 848 6816, e-mail: joseph_matthew.bateman@kcl.ac.uk

^b Samuel Lunenfeld Research Institute, 600 University Avenue, Room 884, Toronto, Ontario M5G 1X5 (Canada)

Received 25 January 2006; received after revision 29 March 2006; accepted 2 May 2006

Online First 19 June 2006

Keywords. Insulin, neurogenesis, IGF, MAPK, *Drosophila*.

Introduction

A fundamental challenge during the development of any complex organism is the coordination of proliferation and differentiation. In the case of neurogenesis, cells must exit the cell cycle and undergo a complex programme of gene expression and morphological changes. This requires the action of multiple secreted ligands which, by binding to their target receptors on the cell surface, control the course of neuronal cell fate in a spatiotemporal manner. Neurogenic organs are wholly dependent on prior proliferation to provide enough cells to generate the mature tissue. There are often assumed to be two sets of independent signalling pathways: one which controls proliferation and a second which controls differentiation. In this context, neuronal differentiation might be seen as a default pathway that occurs as a result of growth factor removal. Surprisingly, however, the same pathway often regulates both proliferation *and* differentiation. In this review we discuss the role of the insulin receptor (IR) and the type I insulin-like growth factor receptor (IGF-IR) receptor tyrosine kinases (RTKs) in neuronal differentiation by comparing knowledge about vertebrates with insight gained from studies in *Drosophila*. Evidence from vertebrates and flies suggests that, in certain developmental contexts and cell types, IR/IGF-IR signalling plays an important role in the differentiation of neurons.

Insulin/IGF signalling in vertebrate neurogenesis

Although the role of IR and IGF-IR signalling in cell proliferation has been clearly demonstrated, the potential role of this group of RTKs in neuronal differentiation has received less attention. Insulin is best known for its role in glucose uptake and metabolism, whereas the insulin-like growth factors (IGFs) are well characterised as growth-promoting peptides [1]. Expression studies of the IR and IGF-IR have demonstrated that both of these RTKs are expressed in the nervous system [2, 3], suggesting that they function in neuronal development. The IR is widely expressed throughout the adult brain and concentrated expression is found in the hypothalamus, olfactory bulb and pituitary [3–5]. In addition, the IGF-IR is expressed in many embryonic tissues but high levels of expression are seen in the developing cerebellum, midbrain, olfactory bulb and the ventral floorplate of the hindbrain [2]. In cultured cells, insulin and IGF-I do not always act as mitogens. For example, in mouse fibroblast cell lines, insulin and IGF-I are very poor mitogens [6]. Insulin and IGF-I can also activate neurogenesis in ex vivo and cultured cell lines [6–11]. H19-7 rat hippocampal cells proliferate at 34 °C in response to serum and differentiate to a neuronal phenotype at 39 °C when treated with basic fibroblast growth factor (bFGF). However, expression of the IGF-IR allows HC19-7 cells to differentiate at 39 °C in response to IGF-I independent of bFGF [9]. In E14 mouse striatal primary neural stem cells (NSCs), the action of insulin/IGF-I to activate either proliferation

* Corresponding author.

or differentiation is dependent on the passage number of the cells. NSCs isolated from neurospheres after two rounds of culture for 1 week differentiate to a neuronal phenotype in response to treatment with IGF-I [7]. Interestingly, the neurogenic action of IGF-I could be potentiated by the addition of brain-derived neurotrophic factor (BDNF), suggesting that these factors can act synergistically to promote differentiation. Conversely, treatment of similar NSCs from primary cultures with IGF-I caused individual cells to proliferate rapidly rather than differentiate [8]. Therefore, the ability of insulin/IGF to promote either differentiation or proliferation depends on the cell type and conditions.

What do the phenotypes of *Ir* and *Igflr* mutant animals tell us about the role of these RTKs in neurogenesis? *Ir*^{-/-} null mice develop normally but die shortly after birth due to severe diabetic ketoacidosis [12], suggesting that the IR is not required for neuronal development. Moreover, a neuron-specific disruption of the *Ir* gene in mice did not affect brain development or neuronal survival [13]. In contrast, *Igflr*^{-/-} mice have reduced brain size and altered brain structures, including a marked increase in the density of neural cells in the spinal cord and brainstem [14]. Furthermore, detailed examination of cochlear development has shown that development of this sensory organ is severely impaired in *Igflr*^{-/-} mice [15]. A significant decrease in the number of auditory neurons along with aberrant expression of early neural markers suggests that neuronal differentiation in the inner ear is delayed in these mice. Recent studies have also shown that IGF-I is required for differentiation of neuroblasts in the otic vesicle in chick [16]. Moreover, differentiation of neurons derived from mouse olfactory bulb stem cells requires IGF-I [17]. Thus, in mice the IGF-IR seems to be essential for correct central nervous system (CNS) development, while the IR may either be redundant or play a more subtle role.

What are the intracellular signalling cascades by which the IR and IGF-IR RTKs have the potential to control differentiation? In mammalian systems, insulin stimulation has been shown to cause activation of the Ras/mitogen-activated protein kinase (MAPK) pathway [18–20]. Activation of MAPK by the IR is independent of the role of this receptor in glucose homeostasis since inhibition of MAPK activation does not affect the metabolic actions of insulin [21]. Ligand binding to the IR results in tyrosine phosphorylation of the insulin receptor substrate (IRS) proteins and/or Shc, which, through the adaptor protein Grb2, results in recruitment to the membrane of SOS for the activation of Ras (Fig. 1) [22, 23]. MAPK activation is the most well defined route by which IR/IGF-IR signalling might control neurogenesis during development. The first *in vivo* evidence for insulin stimulation of Ras came from the demonstration that insulin-induced *Xenopus* oocyte maturation is blocked by an antibody which

inhibits Ras [24]. More recently, knock-out mice studies have shown that MAPK activation by insulin *in vivo* is dependent on IRS-1 [25]. In cultured cells, activation of MAPK is required for nerve growth factor (NGF)/epidermal growth factor (EGF)-dependent differentiation of PC12 cells [26]. Activation of MAPK in PC12 cells causes phosphorylation of target transcription factors and consequent reprogramming of gene expression to a neuronal fate [27]. Activation of MAPK by an IR/IGF-IR receptor-dependent mechanism has the potential to activate a similar neurogenic switch in target cells in the developing nervous system.

The other pathway which is activated by insulin/IGF receptor stimulation is PI3K/TOR signalling (Fig. 1). PI3K/TOR kinase signalling is known to regulate growth through the control of ribosome biogenesis and protein synthesis [28]. PI3K catalyses the conversion of PIP2 to PIP3, a process which is reversed by the lipid phosphatase PTEN. Growth control is mediated through TOR by the activation of S6K and the translation initiation factor eIF4E. The possible role of PTEN in the nervous system has been studied by several groups using conditional knock-out strategies. Although PTEN is not essential for cell fate determination in the CNS overall [29, 30], a dramatic effect was observed in glial cells. Yue et al. [31] used GFAP-cre to generate *pten*^{-/-} cells in the CNS and observed premature differentiation of Bergmann glia in the early postnatal brain. The premature differentiation of *pten*^{-/-} glia resulted in layering defects and subsequent aberrant migration of granule neurons. These data support a role for PTEN acting as a positive regulator of differentiation in certain cell types in the brain.




Figure 1. Potential pathways by which insulin/IGF signalling can regulate neurogenesis.

Insulin receptor signalling in *Drosophila*

Unlike vertebrates, *Drosophila* has a single RTK of the insulin receptor family (DInr). Expression of the DInr is ubiquitous during early stages of embryogenesis, but becomes enriched in the developing nervous system [32, 33]. The DInr can be activated by one of seven *Drosophila* insulin-like peptides (DILPS). Three of the DILPS are produced by seven neurosecretory cells within the brain. Flies in which these neurosecretory cells have been ablated are phenotypically similar to *dInr* mutants and have some features that are analogous to diabetes [34]. The DInr is required for growth during development and to attain full adult size [35]. Hypomorphic *dInr* mutants are developmentally delayed and have reduced size due to decreased cell number and cell size [36], suggesting that the role of the DInr during development is analogous to the IGF-IR. *dInr*^{-/-} animals have defects in the development of embryonic central and peripheral nervous systems [32]. Unfortunately, this phenotype has not been studied in detail and so it is not clear whether embryonic neurons in *dInr* mutants are lost due to an inhibition of neurogenesis, proliferation, or indirectly through neuroblast apoptosis. In the developing eye, photoreceptor neurons do not absolutely require the DInr for neurogenesis; however, in the absence of the DInr, neuronal differentiation is significantly delayed [37]. Unlike activation of Ras/MAPK signalling, which is able to induce ectopic neurogenesis in the eye field, activation of DInr signalling modulates the timing of the differentiation programme. These findings suggest that the role of DInr signalling in neuronal differentiation is to act synergistically with other neurogenic pathways, such as EGF receptor (EGFR) signalling.

Does the DInr regulate the same intracellular signal transduction pathways as its mammalian counterparts? In *Drosophila* tissue culture cells, stimulation with mammalian insulin causes rapid phosphorylation of MAPK [38–40]; however, to date this has not been reported *in vivo*. Over-activation of MAPK signalling in the developing eye in *Drosophila* causes the formation of ectopic photoreceptor neurons [41, 42]. Over-expression of the DInr in the eye causes over-proliferation and, although the normal complement of photoreceptors are produced, there is a disruption in the patterning of the eye [36]. Interestingly, the patterning defect caused by over-expression of the DInr is similar to the planar cell polarity defects seen with mutations in EGFR signalling [43, 44], suggesting there may be cross-talk between these two pathways *in vivo*.

Chico, the *Drosophila* IRS, contains conserved putative binding sites for Drk, the homologue of the adaptor protein Grb2 [45]. Oldham et al. [46] generated transgenic flies containing a version of *chico* in which the putative Drk-binding site had been mutated, and found that this mutant was able to fully rescue the growth defects of

chico^{-/-} flies. In contrast, if the binding site for the regulatory subunit of PI3K (p60) in Chico was mutated, there was a complete loss of function. Why then is the Drk-binding site in the *Drosophila* IRS conserved? It is possible that a low level of MAPK activation may contribute to the ability of the DInr to control proliferation, although this is unlikely since loss of *pten* was able to completely rescue the growth defects caused by loss of the *dInr* [46]. Alternatively, the DInr may only activate MAPK in certain developmental contexts, such as embryonic development. Interestingly, loss of one copy of the *dInr* gene was able to dominantly suppress the embryonic lethality caused by over-expression of Ras^{V12} [47].

Work in the last few years has shown that, as in vertebrates, activation of the *Drosophila* PI3K is dependent on DInr signalling [28]. Signalling downstream of PI3K via AKT (PKB), the tuberous sclerosis complex (TSC) and TOR kinase is also highly conserved in *Drosophila*. As in mammals, the DInr pathway regulates the growth of flies via S6K and eIF4E. Moreover, the timing of photoreceptor neurogenesis in the developing eye is controlled by the DInr through a PI3K-TOR-dependent mechanism [37]. How might DInr signalling control neuronal differentiation through PI3K-AKT-TOR signalling? One of the targets of AKT is the forkhead transcription factor FOXO. FOXO regulates the transcription of a diverse set of genes that are involved in processes such as control of cell proliferation and apoptosis [48]. In certain developmental contexts, FOXO may be able to regulate the transcription of neurogenic genes, thereby mediating a neurogenic response to DInr stimulation. Alternatively, PI3K/TOR signalling may inter-connect with the Ras/MAPK pathway. Recent studies in mammalian tissue culture cells and in *Drosophila* have demonstrated the existence of a positive feedback loop by which S6K is able to regulate IRS levels and phosphorylation [49]. This feedback loop gives PI3K-AKT-TOR signalling the potential to control MAPK activation (and potentially neurogenesis) by modulating the activity of the IRS.

Conclusions and future directions

Can we assimilate the studies from vertebrates and flies to gain a greater understanding of the role of insulin/IGF signalling in neurogenesis? In both systems, *Ir/Igf1r* null animals show defects in CNS development. Further studies are needed, however, to characterise these defects in detail. Such studies should help to correlate the known expression patterns of the IR and IGF-IR with the affected neuronal/glial cell types. The mechanism of action by which insulin/IGF signalling controls differentiation is most easily addressed in cell culture systems. Vertebrate cell culture studies suggest that insulin/IGF-stimulated differentiation may occur through activation of the Ras/

MAPK pathway. Analogous studies have not been performed in *Drosophila* cells although the increasing availability of *Drosophila* neuronal cell lines in combination with RNAi technology provides an excellent opportunity to identify novel neural targets of the DInr. Vertebrate whole-animal models also show that insulin activates the Ras/MAPK pathway. *In vivo* studies in *Drosophila* have yet to demonstrate that the DInr can activate the Ras/MAPK pathway; however, our recent data suggest that in the *Drosophila* eye, the DInr pathway can regulate Ras/MAPK signalling through a transcriptional mechanism that requires TOR [unpublished results]. In conclusion, there is good evidence from both vertebrates and flies to suggest that insulin/IGF signalling has a conserved role in both proliferation and neuronal differentiation. The choice between proliferation and neurogenesis depends on the particular cell type or developmental context. The contribution of insulin/IGF signalling to neurogenesis may be context and/or cell type specific; however, the importance of fine spatiotemporal control of neuronal differentiation means that understanding the role of this pathway is of major importance. Small alterations in the wiring of the brain can have profound consequences on function, and there are abundant data to suggest that the cues for axonal guidance alter over developmental time. In addition, the competence of neural progenitors to produce neurons of different fates is altered over time during development [reviewed in ref. 50]. To generate a structure of such intricacy as the brain, growth and differentiation must be coordinated, and the insulin/IGF signalling pathway appears to have just such a function. The challenge for the future is to understand molecularly how proliferation and differentiation are coordinated by a single pathway.

- 1 Russo, V. C., Gluckman, P. D., Feldman, E. L. and Werther, G. A. (2005) The insulin-like growth factor system and its pleiotropic functions in brain. *Endocr. Rev.* 26, 916–943.
- 2 Bondy, C. A., Werner, H., Roberts, C. T. Jr and LeRoith, D. (1990) Cellular pattern of insulin-like growth factor-I (IGF-I) and type I IGF receptor gene expression in early organogenesis: comparison with IGF-II gene expression. *Mol. Endocrinol.* 4, 1386–1398.
- 3 Havrankova, J., Schmechel, D., Roth, J. and Brownstein, M. (1978) Identification of insulin in rat brain. *Proc. Natl. Acad. Sci. USA* 75, 5737–5741.
- 4 Baskin, D. G., Porte, D. Jr, Guest, K. and Dorsa, D. M. (1983) Regional concentrations of insulin in the rat brain. *Endocrinology* 112, 898–903.
- 5 van Houten, M., Posner, B. I., Kopriwa, B. M. and Brawer, J. R. (1979) Insulin-binding sites in the rat brain: *in vivo* localization to the circumventricular organs by quantitative radioautography. *Endocrinology* 105, 666–673.
- 6 Benito, M., Valverde, A. M. and Lorenzo, M. (1996) IGF-I: a mitogen also involved in differentiation processes in mammalian cells. *Int. J. Biochem. Cell Biol.* 28, 499–510.
- 7 Arsenijevic, Y. and Weiss, S. (1998) Insulin-like growth factor-I is a differentiation factor for postmitotic CNS stem cell-derived neuronal precursors: distinct actions from those of brain-derived neurotrophic factor. *J. Neurosci.* 18, 2118–2128.
- 8 Arsenijevic, Y., Weiss, S., Schneider, B. and Aebischer, P. (2001) Insulin-like growth factor-I is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2. *J. Neurosci.* 21, 7194–7202.
- 9 Morriore, A., Romano, G., Navarro, M., Reiss, K., Valentinis, B., Dews, M., Eves, E., Rosner, M. R. and Baserga, R. (2000) Insulin-like growth factor I receptor signaling in differentiation of neuronal H19-7 cells. *Cancer Res.* 60, 2263–2272.
- 10 Pahlman, S., Meyerson, G., Lindgren, E., Schalling, M. and Johansson, I. (1991) Insulin-like growth factor I shifts from promoting cell division to potentiating maturation during neuronal differentiation. *Proc. Natl. Acad. Sci. USA* 88, 9994–9998.
- 11 Hernandez-Sanchez, C., Lopez-Carranza, A., Alarcon, C., de La Rosa, E. J. and de Pablo, F. (1995) Autocrine/paracrine role of insulin-related growth factors in neurogenesis: local expression and effects on cell proliferation and differentiation in retina. *Proc. Natl. Acad. Sci. USA* 92, 9834–9838.
- 12 Accili, D., Drago, J., Lee, E. J., Johnson, M. D., Cool, M. H., Salvatore, P., Asico, L. D., Jose, P. A., Taylor, S. I. and Westphal H. (1996) Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. *Nat. Genet.* 12, 106–109.
- 13 Bruning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Muller-Wieland D. and Kahn, C. R. (2000) Role of brain insulin receptor in control of body weight and reproduction. *Science* 289, 2122–2125.
- 14 Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J. and Efstratiadis, A. (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type I IGF receptor (Igf1r). *Cell* 75, 59–72.
- 15 Camarero, G., Avendano, C., Fernandez-Moreno, C., Villar, A., Contreras, J., de Pablo, F., Pichel, J. G. and Varela-Nieto, I. (2001) Delayed inner ear maturation and neuronal loss in postnatal Igf-1-deficient mice. *J. Neurosci.* 21, 7630–7641.
- 16 Camarero, G., Leon, Y., Gorospe, I., De Pablo, F., Alsina, B., Giraldez, F. and Varela-Nieto, I. (2003) Insulin-like growth factor 1 is required for survival of transit-amplifying neuroblasts and differentiation of otic neurons. *Dev. Biol.* 262, 242–253.
- 17 Vicario-Abejon, C., Yusta-Boyo, M. J., Fernandez-Moreno, C. and de Pablo, F. (2003) Locally born olfactory bulb stem cells proliferate in response to insulin-related factors and require endogenous insulin-like growth factor-I for differentiation into neurons and glia. *J. Neurosci.* 23, 895–906.
- 18 Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radziejewska, E., Morgenbesser S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H. and Yancopoulos, G. D. (1991) ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. *Cell* 65, 663–675.
- 19 Saltiel, A. R. and Kahn, C. R. (2001) Insulin signalling and the regulation of glucose and lipid metabolism. *Nature* 414, 799–806.
- 20 Yenush, L. and White, M. F. (1997) The IRS-signalling system during insulin and cytokine action. *Bioessays* 19, 491–500.
- 21 Lazar, D. F., Wiese, R. J., Brady, M. J., Mastick, C. C., Waters, S. B., Yamauchi, K., Pessin, J. E., Cuatrecasas P. and Saltiel, A. R. (1995) Mitogen-activated protein kinase inhibition does not block the stimulation of glucose utilization by insulin. *J. Biol. Chem.* 270, 20801–20807.
- 22 Baltensperger, K., Kozma, L. M., Cherniack, A. D., Klarlund, J. K., Chawla, A., Banerjee, U. and Czech, M. P. (1993) Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes. *Science* 260, 1950–1952.
- 23 Skolnik, E. Y., Batzer, A., Li, N., Lee, C. H., Lowenstein, E., Mohammadi, M., Margolis, B. and Schlessinger, J. (1993) The function of GRB2 in linking the insulin receptor to Ras signalling pathways. *Science* 260, 1953–1955.

- 24 Korn, L. J., Siebel, C. W., McCormick, F. and Roth, R. A. (1987) Ras p21 as a potential mediator of insulin action in *Xenopus* oocytes. *Science* 236, 840–843.
- 25 Yamauchi, T., Tobe, K., Tamemoto, H., Ueki, K., Kaburagi, Y., Yamamoto-Honda, R., Takahashi, Y., Yoshizawa, F., Aizawa, S., Akanuma, Y., Sonenberg, N., Yazaki, Y. and Kadowaki, T. (1996) Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. *Mol. Cell. Biol.* 16, 3074–3084.
- 26 Tan, P. B. and Kim, S. K. (1999) Signaling specificity: the RTK/RAS/MAP kinase pathway in metazoans. *Trends Genet.* 15, 145–149.
- 27 Treisman, R. (1996) Regulation of transcription by MAP kinase cascades. *Curr. Opin. Cell Biol.* 8, 205–215.
- 28 Leever, S. J. and Hafen, E. (2004) Growth regulation by insulin and TOR signalling in *Drosophila*. In: *Cell Growth* (Hall, M. N., Raff, R. and Thomas, G., Eds.) pp. 167–192, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.
- 29 Groszer, M., Erickson, R., Scripture-Adams D. D., Lesche, R., Trumpp, A., Zack, J. A., Kornblum, H. I., Liu, X. and Wu, H. (2001) Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene *in vivo*. *Science* 294, 2186–2189.
- 30 Marino, S., Krimpenfort, P., Leung, C., van der Korput, H. A., Trapman, J., Camenisch, I., Berns, A. and Brandner, S. (2002) PTEN is essential for cell migration but not for fate determination and tumorigenesis in the cerebellum. *Development* 129, 3513–3522.
- 31 Yue, Q., Groszer, M., Gil, J. S., Berk, A. J., Messing, A., Wu, H. and Liu, X. (2005) PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization. *Development* 132, 3281–3291.
- 32 Fernandez, R., Tabarini, D., Azpiazu, N., Frasch, M. and Schlessinger, J. (1995) The *Drosophila* insulin receptor homolog: a gene essential for embryonic development encodes two receptor isoforms with different signaling potential. *EMBO J.* 14, 3373–3384.
- 33 Garofalo, R. S. and Rosen, O. M. (1988) Tissue localization of *Drosophila melanogaster* insulin receptor transcripts during development. *Mol. Cell. Biol.* 8, 1638–1647.
- 34 Rulifson, E. J., Kim, S. K. and Nusse, R. (2002) Ablation of insulin-producing neurons in flies: growth and diabetic phenotypes. *Science* 296, 1118–1120.
- 35 Chen, C., Jack, J. and Garofalo, R. S. (1996) The *Drosophila* insulin receptor is required for normal growth. *Endocrinology* 137, 846–856.
- 36 Brogiolo, W., Stocker, H., Ikeya, T., Rintelen, F., Fernandez, R. and Hafen, E. (2001) An evolutionarily conserved function of the *Drosophila* insulin receptor and insulin-like peptides in growth control. *Curr. Biol.* 11, 213–221.
- 37 Bateman, J. M. and McNeill, H. (2004) Temporal control of differentiation by the insulin receptor/tor pathway in *Drosophila*. *Cell* 119, 87–96.
- 38 Bikopoulos, G., Ceddia, R. B., Sweeney, G. and Hilliker, A. J. (2004) Insulin reduces apoptosis and increases DNA synthesis and cell size via distinct signalling pathways in *Drosophila* Kc cells. *Cell Prolif.* 37, 307–316.
- 39 Kim, S. E., Cho, J. Y., Kim, K. S., Lee, S. J., Lee, K. H. and Choi, K. Y. (2004) *Drosophila* PI3 kinase and Akt involved in insulin-stimulated proliferation and ERK pathway activation in Schneider cells. *Cell Signal.* 16, 1309–1317.
- 40 Kwon, H. B., Kim, S. H., Kim, S. E., Jang, I. H., Ahn, Y., Lee, W. J. and Choi, K. Y. (2002) *Drosophila* extracellular signal-regulated kinase involves the insulin-mediated proliferation of Schneider cells. *J. Biol. Chem.* 277, 14853–14858.
- 41 Dominguez, M., Wasserman, J. D. and Freeman, M. (1998) Multiple functions of the EGF receptor in *Drosophila* eye development. *Curr. Biol.* 8, 1039–1048.
- 42 Halfar, K., Rommel, C., Stocker, H. and Hafen, E. (2001) Ras controls growth, survival and differentiation in the *Drosophila* eye by different thresholds of MAP kinase activity. *Development* 128, 1687–1696.
- 43 Gaengel, K. and Mlodzik, M. (2003) Egfr signaling regulates ommatidial rotation and cell motility in the *Drosophila* eye via MAPK/Pnt signaling and the Ras effector Canoe/AF6. *Development* 130, 5413–5423.
- 44 Brown, K. E. and Freeman, M. (2003) Egfr signalling defines a protective function for ommatidial orientation in the *Drosophila* eye. *Development* 130, 5401–5412.
- 45 Bohni, R., Riesgo-Escovar, J., Oldham, S., Brogiolo, W., Stocker, H., Andruss, B. F., Beckingham, K. and Hafen, E. (1999) Autonomous control of cell and organ size by CHICO, a *Drosophila* homolog of vertebrate. IRS1-4. *Cell* 97, 865–875.
- 46 Oldham, S., Stocker, H., Laffargue, M., Wittwer, F., Wymann, M. and Hafen, E. (2002) The *Drosophila* insulin/IGF receptor controls growth and size by modulating PtdInsP(3) levels. *Development* 129, 4103–4109.
- 47 Maixner, A., Hecker, T. P., Phan, Q. N. and Wassarman, D. A. (1998) A screen for mutations that prevent lethality caused by expression of activated sevenless and Ras1 in the *Drosophila* embryo. *Dev. Genet.* 23, 347–361.
- 48 Neufeld, T. P. (2003) Shrinkage control: regulation of insulin-mediated growth by FOXO transcription factors. *J. Biol.* 2, 18.
- 49 Manning, B. D. (2004) Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. *J. Cell Biol.* 167, 399–403.
- 50 Cremisi, F., Philpott, A. and Ohnuma, S. (2003) Cell cycle and cell fate interactions in neural development. *Curr. Opin. Neurobiol.* 13, 26–33.

